文献速递乳腺癌

高危乳腺癌辅助剂量密集AC与TAC方案比较:MATADOR随机试验首次结果

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
PubMed 文献 · Eur J Cancer · 2018-01-01

MATADOR试验将664例pT1-3、pN0-3乳腺癌患者随机分配至6周期剂量密集多柔比星+环磷酰胺(ddAC)或6周期多西他赛+多柔比星+环磷酰胺(TAC)辅助化疗。中位随访7年,5年无复发生存率ddAC组87%、TAC组88%(HR 0.89,P=0.53),总生存率分别为93%和94%(HR 0.89,P=0.61),无显著差异。

要点

  • 6周期ddAC与TAC在高危乳腺癌中5年RFS和OS无显著差异。
  • ddAC组贫血更常见,TAC组腹泻和周围神经病变更常见。

核心结论

  • 在高危乳腺癌患者中,6周期辅助ddAC与TAC相比,中位随访7年时RFS和OS无显著差异。

研究设计与样本

  • 多中心随机生物标志物发现试验MATADOR(BOOG 2004-04),纳入pT1-3、pN0-3乳腺癌患者664例,1:1随机至ddAC或TAC组。

主要发现

  • 5年RFS:ddAC组87%(95%CI 83%-91%),TAC组88%(84%-92%),HR 0.89(95%CI 0.62-1.28),P=0.53。
  • 5年OS:ddAC组93%(90%-96%),TAC组94%(91%-97%),HR 0.89(95%CI 0.57-1.39),P=0.61。
  • 贫血在ddAC组更常见:62/327例(18.9%) vs 15/319例(4.7%),P<0.001。
  • 腹泻在TAC组更常见:53例(16.6%) vs 21例(6.4%),P<0.001。
  • 周围神经病变在TAC组更常见:46例(14.4%) vs 15例(4.6%),P<0.001。

关键数值与推荐

  • ddAC方案:多柔比星60 mg/m2+环磷酰胺600 mg/m2,每2周一次,共6周期。
  • TAC方案:多西他赛75 mg/m2+多柔比星50 mg/m2+环磷酰胺500 mg/m2,每3周一次,共6周期。

临床怎么用

  • 对于高危乳腺癌辅助化疗,ddAC与TAC疗效相当,方案选择可结合毒性谱个体化考虑。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dose-dense administration of chemotherapy and the addition of taxanes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival substantially. However, clinical trials directly comparing the additive value of taxanes with dose-dense anthracycline-based chemotherapy are lacking. PATIENTS AND METHODS: In the multicentre, randomised, biomarker discovery Microarray Analysis in breast cancer to Tailor Adjuvant Drugs Or Regimens (MATADOR) trial, patients with pT1-3, pN0-3 breast cancer were randomised (1:1) between six adjuvant cycles of doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC) and six cycles of docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC). The primary objective was to discover a predictive gene expression profile for ddAC and TAC benefit. Here we report the preplanned secondary end-point recurrence-free survival (RFS) and overall survival (OS). RESULTS: Between 2004 and 2012, 664 patients were randomised. At 5 years, RFS was 87% (95% confidence interval [CI] 83%-91%) in the ddAC-treated patients and 88% (84-92%) in the TAC-treated subgroup (hazard ratio [HR] 0.89, 95% CI 0.62-1.28, P = 0.53). OS at 5 years was 93% (90%-96%) in the ddAC-treated and 94% (91%-97%) in the TAC-treated patients (HR 0.89, 95% CI 0.57-1.39, P = 0.61). Anaemia was more frequent in ddAC-treated patients (62/327 patients [18.9%] versus 15/319 patients [4.7%], P < 0.001) and diarrhoea (21 [6.4%] versus 53 [16.6%], P<0.001) and peripheral neuropathy (15 [4.6%] versus 46 [14.4%], P < 0.001) were observed more often in TAC-treated patients. CONCLUSIONS: With a median follow-up of 7 years, no significant differences in RFS and OS were observed between six adjuvant cycles of ddAC and TAC in high-risk breast cancer patients. TRIAL REGISTRATION NUMBERS: ISRCTN61893718 and BOOG 2004-04.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Rossum AGJ, Kok M, van Werkhoven E, et al. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04). Eur J Cancer. 2018. PMID: 30125761. doi:10.1016/j.ejca.2018.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。